Skip to main content

Translational medicines ‘Ecosystem’

Section edited by Vijay Mahant

The Translational Medicines 'Ecosystem' section aims to provide a forum for the topics spanning the translational research ecosystem beyond academia. The section will include both research and opinions about the role of patients, government policies, healthcare providers, bio-industries such as biotechnology and pharmaceutical companies, regulatory agencies, ethics, payers, investors and academia in advancing novel medicines. Particular focus area will include opportunities and challenges in collaborating with industry and the role of stakeholders in the translational research “ecosystem”.

  1. Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed a...

    Authors: Åslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjørge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Grønlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Dønnem, Espen Enerly, Åsmund Flobak…
    Citation: Journal of Translational Medicine 2022 20:225

    The Correction to this article has been published in Journal of Translational Medicine 2022 20:317

  2. This paper is a report of recommendations for addressing translational challenges in amyloid disease research. They were developed during and following an international online workshop organized by the LINXS I...

    Authors: Miriam Solomon, Vito Foderà, Annette Eva Langkilde, Perry Elliott, Fabrizio Tagliavini, Trevor Forsyth, Oxana Klementieva and Vittorio Bellotti
    Citation: Journal of Translational Medicine 2022 20:213
  3. To drive translational medicine, modern day biobanks need to integrate with other sources of data (clinical, genomics) to support novel data-intensive research. Currently, vast amounts of research and clinical...

    Authors: Rebecca Asiimwe, Stephanie Lam, Samuel Leung, Shanzhao Wang, Rachel Wan, Anna Tinker, Jessica N. McAlpine, Michelle M. M. Woo, David G. Huntsman and Aline Talhouk
    Citation: Journal of Translational Medicine 2021 19:493
  4. The evaluation of translational health research is important for various reasons such as the research impact assessment, research funding allocation, accountability, and strategic research policy formulation. ...

    Authors: Vasiliki Kiparoglou, Laurence A. Brown, Helen McShane, Keith M. Channon and Syed Ghulam Sarwar Shah
    Citation: Journal of Translational Medicine 2021 19:483
  5. Translational research is an ideology focussed on streamlining the transition of novel research into clinical practice to ultimately benefit populations. Central to this approach is overcoming barriers to rese...

    Authors: Justin B. Senecal, Karen Metcalfe, Kaila Wilson, Indryas Woldie and Lisa A. Porter
    Citation: Journal of Translational Medicine 2021 19:479
  6. This study aimed to explore the collaborative relationship in translational medical research from the perspective of clinicians in China. The findings are expected to help practitioners optimize and experience...

    Authors: Meina Li, Bin Lian, Xiaoxiong Xu, Pan Zhao, Bihan Tang, Chaoqun Hu, Xiang Liu, Wenya Yu and Lulu Zhang
    Citation: Journal of Translational Medicine 2021 19:247
  7. In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally chan...

    Authors: Dominik Hartl, Valeria de Luca, Anna Kostikova, Jason Laramie, Scott Kennedy, Enrico Ferrero, Richard Siegel, Martin Fink, Sohail Ahmed, John Millholland, Alexander Schuhmacher, Markus Hinder, Luca Piali and Adrian Roth
    Citation: Journal of Translational Medicine 2021 19:245
  8. Translational research is a process of applying knowledge from basic biology and clinical trials to techniques and tools that address critical medical needs. Translational research is less explored in the Ugan...

    Authors: Richard Kwizera, Emmanuel Mande, Denis Omali, Samuel Okurut, Sheila Nabweyambo, Rose Nabatanzi, Damalie Nakanjako and David B. Meya
    Citation: Journal of Translational Medicine 2021 19:76
  9. The vast majority of good science and excellent ideas do not translate into products. Many good products that have the potential to assist in diagnosis and therapy do not mature into everyday care. This often ...

    Authors: Yaron Ilan
    Citation: Journal of Translational Medicine 2021 19:55
  10. Defining and protecting participants’ rights is the aim of several ethical codices and legal regulations. According to these regulations, the Informed Consent (IC) is an inevitable element of research with hum...

    Authors: Henriette Rau, Lars Geidel, Martin Bialke, Arne Blumentritt, Martin Langanke, Wenke Liedtke, Sandra Pasewald, Dana Stahl, Thomas Bahls, Christian Maier, Hans-Ulrich Prokosch and Wolfgang Hoffmann
    Citation: Journal of Translational Medicine 2020 18:287
  11. The “Right-to-Try” experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to man...

    Authors: Vijay Mahant
    Citation: Journal of Translational Medicine 2020 18:253
  12. This commentary presents the vision of the International Consortium for Personalised Medicine (ICPerMed) on how personalised medicine (PM) will lead to the next generation of healthcare by 2030. This vision fo...

    Authors: Astrid M. Vicente, Wolfgang Ballensiefen and Jan-Ingvar Jönsson
    Citation: Journal of Translational Medicine 2020 18:180